DJ IMV Reports Positive Data for Covid-19 Vaccine Candidate
By Chris Wack
IMV Inc. said Monday it is encouraged by data generated so far for its vaccine candidate, DPX-Covid-19, for the prevention of Covid-19 infection.
The biopharmaceutical company said it has successfully completed preclinical safety and good laboratory practice, or GLP, toxicology studies, as well as immunogenicity and challenge studies confirming a favorable safety profile and potential for the long duration of antibody titers and protection against SARS-CoV-2.
IMV said it is planning to conduct complementary preclinical studies including testing on new variants and will provide an update in the first quarter of 2021 on its revised clinical plan.
None of the recent mutations reported in U.K. or in Denmark are in the areas of the four selected peptides in DPX-Covid-19. By targeting areas less prone to mutations, DPX-Covid-19 has potential to offer protection against a broader range of circulating variants, the company said.
IMV said the completed safety studies confirmed a favorable safety profile and showed potential for long-term protection with antibody titers maintained throughout the duration of studies.
The company also said it has entered into a collaboration with a global manufacturing partner and initiated transfer and scale-up activities of DPX-Covid-19 in India and Europe with the anticipated capacity to produce several hundred million doses.
IMV shares were up 30% to $3.94 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 28, 2020 07:27 ET (12:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.